Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting
– Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors – SOUTH SAN FRANCISCO,…
Pharmaceuticals, Biotechnology and Life Sciences
– Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors – SOUTH SAN FRANCISCO,…
Abstract Highlights the Effect of Dose Modification on Response to COPIKTRA in Adult Patients with CLL/SLL After At Least Two…
First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in…
AUSTIN, Texas–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/invivo?src=hash" target="_blank"gt;#invivolt;/agt;–First developed in 2012, Altogen’s liver-targeted in vivo transfection reagent has since been successfully used in…
Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple…
— Methylation Technology Identifies Tumor Tissue of Origin of Multiple Cancer Types with High Accuracy — — Initial Survival Analysis…
First-Time Data from POLO Trial Evaluating LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press…
– Phase I/II study of entrectinib, an investigational medicine, showed responses in all pediatric tumor types harboring neurotrophic tyrosine receptor…
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer,…
Published data in peer-reviewed scientific journal to advance potential cell therapy AgeX-BAT1 for Type II Diabetes and obesity Received $4.5…